Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 13/20 | 0.59 |
| ▸ | TPSB2 | P20231 | 9/20 | 0.59 |
| ▸ | F11 | P03951 | 9/20 | 0.59 |
| ▸ | PLG | P00747 | 1/20 | 0.59 |
| ▸ | PLAU | P00749 | 1/20 | 0.59 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.59 |
| ▸ | F7 | P08709 | 1/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007508 | 0.84 | CFD (0.68) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL31757965 | 0.84 | CFD (0.68) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL16396757 | 0.82 | CFD (0.62) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL2537375 | 0.82 | FFAR1 (0.52) | PTGER1FFAR1FFAR4 | |
| SCHEMBL13765028 | 0.82 | FFAR4 (0.52) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL16410490 | 0.81 | CFD (0.81) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL16396556 | 0.80 | CFD (0.56) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL16397709 | 0.80 | CFD (0.60) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL1821370 | 0.79 | PTGER1 (0.60) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL16396440 | 0.79 | CFD (0.59) | CFDTPSB2F11PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| WO-2009125606-A1 | PAI-1 INHIBITOR | 株式会社医薬分子設計研究所 (JP) | 2009-10-15 | — | — | WO | disclosed |
| EP-2080751-A1 | CARBOXYLIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080751-A1 | CARBOXYLIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20080275116-A1 | Carboxilic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080275116-A1 | Carboxilic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | CFD 57/4885TPSB2 696/4885F11 8/4885 |
| US-20080275116-A1 | Carboxilic acid derivatives | SERPINE1, CTRL, SERPINC1 | CFD 115/4885TPSB2 453/4885F11 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.